Charles Schwab’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $75.7K | Sell |
63,636
-47,684
| -43% | -$56.7K | ﹤0.01% | 3427 |
|
|
2025
Q1 | $226K | Sell |
111,320
-2,520
| -2% | -$5.12K | ﹤0.01% | 3244 |
|
|
2024
Q4 | $685K | Sell |
113,840
-2,413
| -2% | -$14.5K | ﹤0.01% | 3044 |
|
|
2024
Q3 | $814K | Sell |
116,253
-27,705
| -19% | -$194K | ﹤0.01% | 2986 |
|
|
2024
Q2 | $835K | Buy |
143,958
+66,576
| +86% | +$386K | ﹤0.01% | 2999 |
|
|
2024
Q1 | $553K | Buy |
77,382
+8,881
| +13% | +$63.5K | ﹤0.01% | 2981 |
|
|
2023
Q4 | $337K | Buy |
68,501
+840
| +1% | +$4.13K | ﹤0.01% | 3195 |
|
|
2023
Q3 | $647K | Buy |
67,661
+6,703
| +11% | +$64.1K | ﹤0.01% | 2949 |
|
|
2023
Q2 | $790K | Buy |
60,958
+2,749
| +5% | +$35.6K | ﹤0.01% | 2845 |
|
|
2023
Q1 | $739K | Buy |
+58,209
| New | +$739K | ﹤0.01% | 2831 |
|